Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483987 | 1.00 | SLC15A2 (0.36) | SLC15A2TERTITGB3ITGA2BCPB2 | |
| SCHEMBL483989 | 0.99 | SLC15A2 (0.36) | SLC15A2TERTITGB3ITGA2BCPB2 | |
| SCHEMBL29591822 | 0.99 | SLC15A2 (0.36) | SLC15A2TERTITGB3ITGA2BCPB2 | |
| SCHEMBL5120251 | 0.99 | SLC15A2 (0.36) | SLC15A2TERTITGB3ITGA2BCPB2 | |
| SCHEMBL30629006 | 0.95 | SLC15A2 (0.39) | SLC15A2TERTITGB3ITGA2BCPB2 | |
| SCHEMBL20397438 | 0.92 | SLC15A2 (0.41) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| SCHEMBL20397507 | 0.92 | SLC15A2 (0.41) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| SCHEMBL29793353 | 0.91 | ITGB3 (0.34) | SLC15A2TERTITGB3ITGA2BCPB2 | |
| SCHEMBL1666820 | 0.91 | SLC15A2 (0.42) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| SCHEMBL483799 | 0.91 | SLC15A2 (0.42) | SLC15A2ITGB3ITGA2BCPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9891187-B1 | Systems and methods for ion measurements | POLESTAR TECHNOLOGIES, INC. (US) | 2018-02-13 | — | — | US | claimed |
| EP-2793828-B1 | MOISTURIZING COMPOSITION COMPRISING AN AMINOPEPTIDE MIXTURE | UNILEVER PLC (GB) | 2016-08-24 | — | — | EP | claimed |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | claimed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | claimed |
| CN-104302271-A | Moisturizing composition comprising an aminopeptide mixture | UNILEVER NV | 2015-01-21 | — | — | CN | claimed |
| EP-2793828-A2 | MOISTURIZING COMPOSITION COMPRISING AN AMINOPEPTIDE MIXTURE | Unilever PLC, a company registered in England and Wales under company no. 41424 (GB) | 2014-10-29 | — | — | EP | claimed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | claimed |
| WO-2013092050-A2 | MOISTURIZING COMPOSITION COMPRISING AN AMINOPEPTIDE MIXTURE | UNILEVER PLC (GB) | 2013-06-27 | — | — | WO | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| JP-5331035-A | — | — | None | — | — | JP | disclosed |
| WO-2022060294-A1 | A METHOD OF PRE-TREATING BIOWASTE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-03-24 | — | — | WO | disclosed |
| EP-2925771-B1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL SCIENT IND RES (IN) | 2021-08-18 | — | — | EP | disclosed |
| US-9891187-B1 | Systems and methods for ion measurements | POLESTAR TECHNOLOGIES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| JP-H05331035-A | EXTERNAL PREPARATION FOR SKIN | SANSHO SEIYAKU CO LTD | 1993-12-14 | — | — | JP | disclosed |
| EP-0500332-A2 | Novel acylamino acid compounds and a method for their production | NATIONAL FOOD RESEARCH INSTITUTE MINISTRY OF AGRICULTURE, FORESTRY AND FISHERIES (JP) | 1992-08-26 | — | — | EP | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | CNR2, SRM, CNR1 | SLC15A2 3402/4885TERT 4617/4885ITGB3 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.